Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

被引：0
作者：
Christine R. Jenkins
Dirkje S. Postma
Antonio R. Anzueto
Barry J. Make
Stefan Peterson
Göran Eriksson
Peter M. Calverley
机构：
[1] Concord Hospital,Department of Thoracic Medicine
[2] University of Sydney and The George Institute for Global Health,Department of Pulmonary Medicine and Tuberculosis
[3] University of Groningen,Pulmonary Section, Department of Medicine
[4] University Medical Center Groningen,Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health
[5] University of Texas Health Science Center,Department of Respiratory Medicine and Allergology
[6] and South Texas Veterans Health Care System,Clinical Sciences Department
[7] University of Colorado Denver School of Medicine,undefined
[8] StatMind,undefined
[9] University Hospital,undefined
[10] Institute of Ageing and Chronic Disease,undefined
[11] University Hospital Aintree,undefined
来源：
BMC Pulmonary Medicine | / 15卷
关键词：
COPD; Budesonide/formoterol; Exacerbation; Reliever medication; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 151 条
[11]  
Travers D(2006)Clinical assessment of asthma symptom control: review of current assessment instruments J Asthma 43 481-365
[12]  
Weinberger M(2013)Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 347-272
[13]  
Postma D(2011)Symptom variability in patients with severe COPD: a pan-European cross-sectional study Eur Respir J 37 264-90
[14]  
Anzueto A(2001)Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 85-268
[15]  
Calverley P(2012)Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study Respir Med 106 257-750
[16]  
Jenkins C(2009)Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 741-162
[17]  
Make BJ(2010)Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 155-752
[18]  
Sciurba FC(2011)Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respir Res 12 156-1103
[19]  
Jones PW(2012)Efficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPD Chest 141 745-2000
[20]  
Westwood M(2011)Tiotropium versus salmeterol for the prevention of exacerbations of COPD N Engl J Med 364 1093-565
12345678910